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Abstract
Pediatric cancer is becoming increasingly important in low-/middle-income countries
(LMICs), due to the improvement in controlling communicable diseases, decrease infant,
and early childhood mortalities associated with infection and malnutrition.
Worldwide, although much improvement was encountered in many pediatric tumors
particularly acute leukemia that represents the commonest type of cancer in children, this
was not so obvious in CNS tumors, the second most common tumor type. Slow advances
have been achieved to improve treatment end results in pediatric neuro-oncology. This
was largely related to disease under diagnosis, incorrect clinical assessment, improper
staging,  and  lack  of  the  availability  of  appropriate  radiologic,  neurosurgical,  and
radiotherapeutic services in LMICs. Moreover, the need for multidisciplinary team
working together to embalmment unified approved management guidelines, highly
specific care level within a widely accepted quality control measures are of utmost
importance to raise the treatment outcome levels to that of high-income countries (HICs).
Much effort is needed in LMICs to improve the management of pediatric CNS tumors,
decrease the gap, and reach good results already attained by the dedicated centers in
HICs. There are many international organizations and societies that can and are willing
to help in this matter.
In this chapter, an illustration of the obstacles faced by LMIC neuro-oncologists will be
discussed. The different ways and procedures are recommended to improve the general
situation to attain good results similar to that in HICs.
Keywords: neuro-oncology, children, low-/middle-income countries, LMIC, CNS tu‐
mors, brain, late sequelae
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1. Introduction
Pediatric central nervous system (CNS) tumors represent the second most common cancer in
childhood after leukemias. Pediatric cancer is the leading cause of disease-related childhood
mortality in high-income countries (HICs). Furthermore, it is becoming increasingly impor‐
tant in low-/middle-income countries (LMICs) because of the continuing success to decrease
the infant and childhood mortality associated with malnutrition and communicable disease.
Unfortunately, the 80% cure rate for HIC children suffering from cancer does not apply to
many of pediatric patients in LMIC [1]. The barriers to optimize the management of children
with cancer in LMICs to reach the same level as that in HICs were investigated in many
situations; however, minimal advances have been made to improve the treatment and clinical
end results of children especially those with brain tumors. Many factors were identified as
responsible for this failure to achieve such an acceptable level of cure. These were underdiag‐
nosis, abandonment of therapy, incorrect assessment, lack of appropriate radiological,
histopathologic, neurosurgical, radiotherapeutic, and pediatric oncologic services. More
important is the deficiency of the real concept of multidisciplinary care and the team manage‐
ment that definitely contributes negatively to the results of treatment [2]. In many LMICs, a
significant portion of pediatric brain tumors remains undiagnosed and the patients subse‐
quently die of their malignancy. Many others abandoned effective treatment due to different
reasons: financial, social, long distance from the treating center, or being treated with herbal
and unconventional therapy. The identification of these findings will help the development of
targeted strategies, such as increased training and tools for neuropathology, improved access
to neuroimaging and radiotherapy, improve early diagnosis, and optimal collaborate therapy.
Interventions to implement and increase family support may positively contribute on
improvement of outcome.
1.1. Magnitude of the PROBLEM
Underdiagnosis, treatment abandonment, improper assessment, lack of appropriate medical
imaging, histopathologic, neurosurgical, radiotherapeutic pediatric oncologic services
deficiencies, and the deficiency of the multidisciplinary care concept and the team manage‐
ment are well-known barriers that hinder successful neuro-oncologic management that leads
to the obtainment of equivalent clinical end results already achieved in HICs. In addition, in
many patients, treatment may be negatively affected because of poor general health, with the
comorbidity of malnutrition and infections such as human immunodeficiency virus (HIV) and
tuberculosis. Furthermore, the lack of adequate supportive drugs and supplements that
ameliorate the oncologic treatment side effects and preserve a tolerable general condition may
contribute not only in intolerance of therapy but also in lowering the survival rates and quality
of life (QoL) of such patients. The applied treatment protocols have to take these factors and
conditions into account. Protocols applied in HICs may not be optimum and may be even
dangerous in LMICs especially whenever the supportive care is deficient [3]. The aggrega‐
tion of the necessary facilities and properly trained staff in one referral center serving an LMIC
or a large sector of it may be the proper way to serve these children and to raise the stand‐
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ard of care to reach the acceptable level of cure attained in HICs [4]. It is obvious that it is easier,
more convenient, and cheaper to arrange for establishing a referral pediatric neuro-oncolog‐
ic center to be responsible for the welfare of such children. The tremendous improvements in
imaging, surgical approaches, pathological diagnosis, radiotherapy techniques, and chemo‐
therapy drugs in the last three decades have improved survival rates in children with brain
tumors and are attained in such referral centers. Innovations in radiation techniques, includ‐
ing the three-dimensional (3D) radiation therapy (RT) and different forms of intensity-
modulated radiation therapy (IMRT) such as static IMRT, volumetric modulated arc therapy
(VMAT), tomotherapy, cyberknife, and all forms of image-guided radiotherapy, have
contributed to the precise and extremely accurate delivery of the radiation dose to the target
while reducing the dose to the normal brain tissue. These techniques minimize RT-related
toxicities through decreasing the dose to the surrounding functioning structures while
increasing tumor control probability [5].
1.2. Diagnosis delay in CNS tumors
Despite advances in neuroimaging, timely diagnosis of CNS tumors remains a problem even
in HICs. It is obvious that the issue of late diagnosis of CNS tumors is more obvious and more
intense in LMICs. Beyond the usual challenges of nonspecific symptoms, the access to
neuroimaging facilities is the main obstacle that patients and families face. The limited number
of computerized tomography (CT) or magnetic resonance imaging (MRI) scans in LMICs;
prolonged waiting lists, especially in children needing sedation; and high cost of these tests
are among the reasons that delay the diagnosis of brain tumor. Furthermore, in many places,
the imaging study is limited to the brain, regardless of the state-of-art recommendation. It is
exceptional to have preoperative imaging of the spine when a malignant brain tumor such as
medulloblastoma is suspected. Most developing countries lack specialized centers present‐
ing the complete multidisciplinary service equipped with the necessary diagnostic and
treatment tools in hands of experienced staff [6].
The adoption of unified management protocols represents a major drawback. A single referral
neuro-oncologic center in each LMIC that is fully equipped and adequately staffed could serve
the patients in a more professional and efficient way that decrease the cost and improve the
clinical outcome. Aggregation of the needed staff, equipment, and experience together with
standardizing policies, treatment protocols, and managements may be the best way to
overcome the difficulties facing LMIC challenges in pediatric neuro-oncology practice [4]. The
obstacles of long distance and financial needs to access these specialized centers will remain
as a problem that needs effort to be solved. The diagnosis of brain tumor in some LMIC cultures
has a negative perception and stigmatization. Families may abundant treatment and even
referred to cancer center, for the fear of marginalization associated with brain tumor. Stigma
of the false belief that cancer means death or mental and physical disability may influence
parental or family decisions including treatment abandonment. Some cultural preferences
such as treating boys over girls have to be strongly faced.
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Radiotherapy evolved tremendously in the last three to four decades, depending upon the
advances in physics, atomic sciences, materials, engineering, computer science, and telecom‐
munication. Linear accelerator-based RT became the backbone technology. This phase
represented a megavoltage (MV) power race, which would have skin-sparing properties, while
delivering a high dose of radiation at depth. Linear accelerators initiated the new technolo‐
gies of 3D conformal RT, IMRT, and image-guided radiotherapy including the helical
tomotherapy and others [7]. The technique of radiosurgery was developed through com‐
bined efforts of multiple specialties, where multiple cobalt-60 sources were fitted into a helmet-
like configuration with precision beam collimation to produce remarkably tiny and accurate
beams, resulting in the concept of using single-fraction radiation doses for the purposes of
target ablation, which expanded the clinical utility beyond neoplasms into the field of benign
and functional indications.
1.3. Neuroimaging
Neuroimaging is a key tool in the diagnosis and follow-up of neuro-oncologic patients. MRI
and CT are the main imaging modalities involved in neuroimaging diagnosis of these patients.
Nevertheless, in pediatric neuro-oncology MRI ranked superior not only due to lack of
radiation exposure provided by CT but also due to the more significant details of the brain
parenchyma offered by MRI. The standard MRI sequences (T1- and T2-weighted spin-echo in
three planes; axial, coronal, and sagittal). Fluid attenuation inversion recovery (FLAIRE)
sequences followed by post-contrast are usually adopted. These sequences are usually enough
for an accurate differential diagnosis. However, newer sequences and techniques provide
additional information for both the diagnosis and treatment management of difficult and/or
atypical cases [8]. Although gadolinium-based contrast media is not nephrotoxic yet, it is not
advisable for children younger than 2 years [8].
Ideally, post-surgery studies should be performed within the first 48 h after neurosurgical
procedure in order to avoid misinterpretations of residual tumor enhancement with blood
leakage across the blood-brain barrier. Diffusion study, describing the random thermal motion
of the water molecule in tissues, detects the tissue cellularity. It gives a clue about the grade
of the tumor and its cellularity. Diffusion tensor imaging (DTI) allows determination of fiber
bundle directionality (tractography) study [9].
In neuro-oncology, 3D imaging is used for stereotaxy, a technique creating a coordinate system
to guide lesion localization in a surgical procedure or radiotherapy treatment. In order to
reduce morbidity in CNS tumor resection, this technique is usually supplemented by other
maneuvers and techniques such as functional MRI and direct cortical stimulation [8].
MR spectroscopy (MRS) is a technique widely used to assess metabolites in the brain paren‐
chyma and lesions. The results of an MRS acquisition are typically displayed in a graphic of
metabolite peaks. The assessed metabolites are choline, creatine, N-acetylaspartate (NAA), and
lactate. Perfusion technique can be applied with both MRI and CT. Nevertheless, there is a
new MRI sequence called arterial spin labeling (ASL) that can be used to study brain perfu‐
sion without the use of contrast media [10]. The perfusion images are frequently interpreted
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in a color map. The red zones usually demonstrate increased perfusion and the blue zones
decreased perfusion. The perfusion technique differentiates between low- and high-grade
tumors. It is helpful in the differentiation of radiation necrosis (decreased perfusion) from
tumor recurrence (normal to elevated perfusion) and in defining the ideal area for surgical
biopsy, avoiding areas of necrosis.
1.3.1. PET scan and future molecular imaging
Positron emission tomography (PET) and molecular imaging are rapidly developing as new
techniques to evaluate brain tumor. The results provided by PET and molecular imaging
appear to corroborate the findings of MRI studies for decision making in the treatment and
follow-up. The use of a PET scan is often carried out together with low-dose CT images or MRI
to improve the anatomical localization. Common radiopharmaceuticals applied in brain
imaging are fludeoxyglucose (FDG), L-[methyl-11 C] methionine ([11 C]MET), and 3′-
deoxy-3′- [18 F]fluorothymidine ([18 F]FLT). However, FDG applicability in clinical practice
is low as the normal gray matter also demonstrates increased glucose metabolism, effacing
lesions [11].
1.4. Neuropathological services
Experienced pathologists able to differentiate subtypes of pediatric neurological tumors are
deficient in many LMICs. Some diagnoses can be promptly made on standard hematoxylin
and eosin stains based on classic architectural features alone, while more challenging cases
often require ancillary studies including immunohistochemistry, electron microscopy,
cytogenetics, and/or molecular studies. The lack of trained personal and inadequate techni‐
cal equipment is therefore limiting the possibility to achieve an accurate diagnosis in many
places. It is likely that a significant number of children are treated without an adequate
diagnosis that may lead to inadequate or even improper treatment. Microscopic examina‐
tion combined with molecular signatures of these tumors continues to identify and define
features specific to CNS tumor subtypes mostly of great importance, to reach to the proper
diagnosis or the appropriate subtype [12]. Neuro-oncologic telepathology and twinning
between centers in both LMICs and HICs can improve the capacity of accurate histopatho‐
logical diagnosis with little burden on centers shared in these programs [13].
1.5. Radiotherapy services
RT is one of the main critical components of treatment of many pediatric CNS tumors; however,
limited radiotherapy machines and personnel in LMICs make them available only at large
centers with long waiting lists. Delay in starting radiotherapy has a negative impact on
survival. Radiation indications, treatment volumes, and doses are determined according to the
extent of disease, magnitude of excision, tumor histology, pattern of spread, and pattern of
failure in each tumor type and grade. In malignant CNS tumors such as medulloblastoma and
ependymoma, excellent clinical end results have been reported, particularly in patients with
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features denoting standard risk (complete resection, absence of metastatic disease, and no
anaplastic features). The overall survival rates are above 90% in patients with pure germino‐
ma, regardless of metastatic stage, with a combination of chemotherapy and radiation.
However, access to radiation oncology services and the number of functioning radiotherapy
machines available in most LMICs is the main barrier to optimal patient care. It is obvious that
pediatric neuro-oncology programs cannot be implemented in countries, which have no
radiation oncology services. Based on World Bank classification, 139 countries are defined in
the category of LMICs. Out of these, only four (2.9%) have the requisite number of telethera‐
py units and 55 (39.5%) have no RT facilities. It is also worth mentioning that LMICs have 0.71
teletherapy units per million population in contrast to 7.62 teletherapy units per million
population for HICs [14]. A survey of radiotherapy equipment in Africa reported that 52%
(29/56) of their countries had no radiotherapy at all and two-thirds of the MV equipment
available in the continent were located in two countries (Egypt and South Africa) [15].
Moreover, many countries rely on machines that are more than 20 years old, which ques‐
tions their functionality and reliability. The available radiation oncology equipment in the
continent represented 18% of the estimated needs, at time of reporting. The needs increased
more due to rapid increase in the population in many African countries without simultane‐
ous increase in the facilities. Furthermore, appropriate maintenance of the radiation equip‐
ment is a major, problematic issue in countries wherever only one radiotherapy machine is the
case. The treatment could get interrupted for an undetermined period of time and the waiting
times can be prolonged considerably with the machine going out of service. It was estimated
that the LMIC deficit in the teletherapy units was 61.4%, in radiation oncologists 38.9%,
radiation physicists 68.4%, and RT technologists was 66.5% to reach the requirement applied
in HICs [14]. As a consequence, access to radiation and delay in initiation and/or continua‐
tion of radiation treatment are a major problematic issue in most LMICs.
In several situations, pediatric oncologists on trying to overcome the problem of availability
of radiotherapy design protocols that offer postoperative chemotherapy prior to radiation, in
particular for medulloblastoma patients. Although this is not the sound or ideal option, it may
delay or decrease recurrence or dissemination following initial surgery. Another limiting
factor in the management is the number of experienced, well-qualified personnel with an
experience in CNS radiation techniques. Several medulloblastoma trials showed that the
quality of craniospinal radiotherapy (CSI) affects outcome. Therefore, the deficiency of
adequate human resources is another major contributing factor for poor RT capacity in LMICs.
Most reports on radiation oncology personnel availability and training confirm the unavaila‐
bility of enough physicians and staff to deal with the number of patients needing radiation
treatment. This lack of trained personnel with the high patient volume often leads to long
waiting list, disease progression, and poor outcome [16]. In Latin America, a survey report‐
ed the major obstacles for provision of adequate RT as insufficient number of specialists, rather
than a lack of equipment [17]. The insufficient number of radiation oncologists, medical
physicists, and radiation technologists training programs contributed negatively to efficient
number of personnel needed for a decent service. To add to the gloomy picture, it is well
estimated that within the next 10 years, 70% of newly diagnosed cancer patients will be living
in countries that collectively have only 5% of the global resources for cancer control. It is
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estimated that approximately 60% of the world’s patients with cancer, including the pedia‐
tric neuro-oncology patients, do not have access to a complete cancer systemic therapy
regimen, and the percentage is higher for radiotherapy [18].
National cancer control programs, large national or international meetings, or even national
treatment guidelines though of extreme importance, were not adequate to improve the current
situation of neuro-oncology in LMICs. A survey in 167 countries performed by the WHO found
that almost half of these countries had a sort of plan for improving treatment, but national
guidelines are generally lacking while the accessibility and affordability of treatment re‐
mained low in LMICs. In many countries, the national cancer control plans had been de‐
signed according to WHO plan without tailoring it to the local conditions, needs, and
challenges [19, 20].
Engaging in innovative strategic thinking and finding new ways to mobilize and enforcing
local resources to improve the availability and accessibility of cancer care are essential to
overall and balanced cancer control in underserved countries. Most LMICs have some local
resources; however, they may not be adequately mobilized or used in the appropriate manner.
LMICs should not rely entirely on external financial donations. Instead, what is needed is win-
win support and adequate assistance from the affluent organizations or countries, as well as
the pharmaceutical and radiology industrial companies. Assistance better take the form of
technical support for building local capacity, staff training, management guidance, and
research cooperation. Other types of support may include provision of information and
communication technologies, help with obtaining local funds or international grants, and
instructions on how to collaborate on international work in their own countries. (The Win-Win
Initiative of ICEDOC’s Experts in Cancer Without Borders [21].)
Conducting more clinical trials in LMICs, which have the major bulk of pediatric cancer and
neuro-oncologic patients, could shorten the total time needed for conducting clinical trials,
may reduce costs, and could enrich the scientific aspects of those trials with more variability.
It could also help initiate more cost-effective ways in medical services in LMICs that can be
applied even in HICs and could establish a better value cancer care. This may serve double
purposes: improve the quality of both health care and research and prevent the brain drain
experienced by LMICs when their most highly qualified people immigrate to HICs.
Hypofractionation for glioblastoma multiforme (GBM) and diffuse intrinsic pontine glioma
(DIPG) are treatment approaches to improve regional tumor control. This has several
advantages over conventional RT via increased cell death due to the used higher doses per
fraction and reduced tumor repopulation effect consequent to shortening of the overall
treatment time. Haas-Kogan et al. [22] assumed that the α/β ratio equals 2 Gy in p53-mutat‐
ed GBM, and not 7–10 as suggested in other malignant tumor types. Shortened treatment time
has additional significant benefit for patients and their families, because patients with GBM
or DIPG have a limited survival time after the completion of treatment. Shortening treat‐
ment time allows for a better QoL for the patients saving them and their families the burden
of prolonged treatment with all its consequent suffering. However, there may be a risk of
enhanced radioresistance. Hypofractionated radiation has become a frequent choice in the
treatment of GBM and DIPG patients [23–27].
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2. Neuro-oncologic treatment modalities
2.1. Neurosurgery
Neuro-oncology multidisciplinary team discussion allows for a non-bias, more appropriate
decision, evident-based, and tailored according to local situation. The option between
observation, surgical intervention, radiotherapy, chemotherapy, or a combination of these
depends on many factors: tumor type, location, invasiveness as well as the patient’s age and
overall medical condition. Generally, if a tumor is accessible and the morbidity risk is
acceptable, resection should be considered. Neurosurgeons should also actively follow up
patients even if a nonsurgical approach is preferred since their interference might be re‐
quired for treating unsuccessful cases or complications of the chosen modality.
Thorough evaluation of the patient should be performed before a precise neurosurgical
opinion including the clinical condition, neuroimaging studies, and case-specific pertinent
investigations (e.g., serum hormone levels, tumor markers, genetic syndrome features, etc.).
Imaging of the entire neuraxis should be performed, especially for tumors with a tendency for
CNS dissemination such as medulloblastomas, germ cell tumors, ependymomas, and
primitive neuroectodermal tumors (PNETs).
The main objectives of the neurosurgeons are as follows:
– Maximal safe tumor resection when possible
– Histopathological diagnosis
– Treatment of associated conditions (e.g., hydrocephalus)
2.2. Tumor resection
Maximum safe resection can be performed for a lesion that significant neurological impair‐
ments can be avoided after its surgical removal. The patient’s prognosis often correlates with
the extent of resection.
2.3. Histopathological diagnosis
When pediatric CNS tumors are not amenable to surgical resection, a biopsy is required except
in certain situation. Various biopsy techniques have been described and the choice of the
appropriate method mainly depends on tumor location.
A) Stereotactic biopsy
Stereotactic coordinates are used for precise guidance of a needle inside the tumor. This is the
method of choice for deeply located tumors. Stereotactic biopsy may be performed through a
frameless via frameless neuro-navigation device or a metallic head frame-based system. The
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coordinates for adequate placement of the burr hole, the angulation, and depth of the needle
are determined by preoperative images.
B) Open biopsy
Open biopsy can be performed through a small craniotomy that allows for direct access to the
tumor. This method is traditionally used for superficial tumors near or within the cerebral
cortex or when leptomeningeal lesions are identified. Neuro-navigation can help in precise
localization of the tumor in relation to the skull surface.
C) Endoscopic endonasal biopsy
Anterior skull base, sellar region, and tumors invading sinuses can sometimes be accessed
through an endoscopic endonasal approach under general anesthesia.
D) Endoscopic intraventricular biopsy
Tumors located adjacent to or within the ventricular system may be amenable to an endo‐
scopic transventricular approach. This procedure has the advantage of allowing treatment of
associated hydrocephalus via endoscopic venticulostomy and obtaining intraventricular
cerebrospinal fluid (CSF) sample.
2.4. Treatment of hydrocephalus
Due to the mass effect of the tumor causing partial obstruction of the pathway of CSF,
hydrocephalus may develop. The main mechanism of hydrocephalus in the context of CNS
tumors is obstruction of the ventricular system by tumors in the posterior fossa and that located
around the third ventricle [28].
Unstable patients with clinical evidence of elevated ICP should undergo urgent surgery,
inserting external ventricular drain (EVD). The anterior horn of the lateral ventricle is accessed
through an inserted catheter through a skull burr hole and CSF flow is ensured. The EVD is
connected to an external collecting device and allows the excess CSF to be drained [29].
Endoscopic third ventriculostomy (ETV) is another option in hydrocephalus resulting from
posterior fossa or pineal region tumors. An ETV creates a communication between the third
ventricle and the interpeduncular cistern under endoscopic guidance within the ventricular
system [29, 30]. Many patients need permanent diversion of CSF ventriculoperitoneal shunt
(VPS). A proximal catheter is inserted inside the lateral ventricle and is then connected to a
distal catheter tunneled subcutaneously till it reaches the peritoneum. A valve is commonly
inserted between the proximal and the distal catheter and allows for one-way drainage control.
One of the disadvantages of VPSs includes the theoretical risk of intraperitoneal seedling of
neoplastic cells.
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2.5. Spinal cord neoplasms
Intramedullary spinal cord tumors are rare in the pediatric population, representing around
4% of all CNS tumors. Complete surgical excision if feasible or debulking is the general
approach for spinal cord tumors. This procedure often leads to favorable outcome besides
providing sufficient materials for histological diagnosis.
2.6. Management of cystic tumors
Many pediatric CNS tumors are composed of a cystic component or having both cystic and
solid parts. The potential space of the cystic portion creates an isolated microenvironment that
may hinder local treatment (radiotherapy or local chemotherapy). Simple aspiration of the
fluid that composes the cyst may sometimes be a sufficient treatment. Moreover, surgical
resection can be considered for most cystic tumors. Local treatment may be applied includ‐
ing the insertion of a device in which medical therapy will be administered. Specifically, the
use of intracystic radioisotope (radioactive iodine-125 or phosphorus 32) and intracavitary
chemotherapy may be used in selected cases [31]. The main advantage of this treatment is the
low rate of long-term sequelae. Intracystic chemotherapy has been advocated to delay
aggressive treatment such as radical resection or irradiation. This method allows for admin‐
istration of effective therapy (commonly bleomycin or interferon) and abolishes the systemic
toxicity of the systemic chemotherapy and the morbidity of surgical resection. Ommaya
reservoir and instillations of single or multiple doses of active drugs remain the method of
choice for intracystic chemotherapy.
2.7. Management of tumor recurrence
The decision to reoperate on a recurred tumor must be taken in the light of the patient’s life
expectancy and QoL, tumor histology, time length between initial resection and recurrence,
the risks and benefits of a second surgery, and the potential for adjuvant therapy such as
radiotherapy and chemotherapy. Each case should be individually evaluated through
multidisciplinary discussion taking into consideration the patient’s family opinion and
preference. It is worth emphasizing that surgical treatment of recurrent tumors should be
seriously considered as reoperation has improved survival for many tumors such as choroid
plexus tumors, ependymomas, and cerebellar astrocytomas [32–34].
3. Radiotherapy
RT is an essential treatment for most of the neuro-oncology patients. It is frequently used
together with either surgery or chemotherapy or both as a curative treatment. Furthermore,
its use in the palliative setting is vital in many situations for symptom relieving [35]. There are
two types of RT: 1. teletherapy (external beam therapy) treating patients with MV energy, such
as cobalt units and linear accelerators (Linacs), and 2. brachytherapy (internal application of
radioactive sources). It is worth noting that providing effective, reliable, and safe RT is a
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complex, tedious, and expensive procedure. It requires specialized building structures
(bankers) for radiation protection, investment in expensive machinery, dosimetric measure‐
ments, and verification devices used by trained staff capable of efficiently using and optimal‐
ly maintaining such equipment. Furthermore, it requires continuously ongoing quality
assurance and training programs for allocated staff. For these reasons, RT infrastructure in
general may be poor in LMICs, to the extent that only four countries in Africa treat more
than 100 children per year with RT, due to lack of radiation oncology staff, infrastructure, and
services [36]. All RT programs require trained medical physicists and technical engineer staff
to maintain their machines and to provide quality assurance of the treatment machines and
planning programs. Highly trained radiation therapy technicians (RTT) responsible for
planning RT treatment and for operating the machines are extremely needed for the appro‐
priate therapy procedures. Unfortunately, skilled staff is frequently attracted away to better-
resourced countries providing them with superior payment and better standard of living
representing a major issue that needs serious challenge.
Accommodation for the patient and accompanying adult are frequently problematic. In some
countries, accommodation and transport for these patients are frequently offered by charity
organizations. The major challenge that staff face when dealing with pediatric patients in RT
department is the length of time that is needed. Children (and their parents) are more likely
to be cooperative when they are not being rushed, and when the team takes the time to explain
all the details with patience and when accommodating their fears and anxieties.
In general, it is essential to
1. Allocate sufficient time and experienced staff for the daily workflow.
2. Have all the required clinical information at hand.
3. Get the patient’s sedation history from other departments so that it is known before‐
hand whether the child is likely to cooperate, and how easily they can be sedated.
4. It is always helpful to get the child in for a “play” appointment prior to markup day, so
that they familiarize themselves with staff and the machines. A round tour in the
departments may be helpful in getting the patient confident that the procedure is not
painful.
5. Children of 6 years and older will generally cooperate without sedation, especially if the
parents help to prepare them. They should always be told the precise steps of what will
happen to them during the process. The best person to convince the child is a colleague
child patient who receives RT without anesthesia.
6. Children under 5 years of age usually need sedation. Between 5 and 6 years is variable.
7. Obtaining an anesthetist on a daily basis for radiotherapy treatments may be very difficult
in many institutions [37].
Anesthesia may be oral or intravenous. The American Society of Anesthesiologists has
proposed a grading system for sedation use as follows: [38].
1. Minimal sedation/anxiolysis.






For the two-dimensional (2D) RT, the procedure is a clinical anatomical decision-making
process, determining the tumor location as well as the proximity of critical normal tissues.
Setting up two orthogonal radiation beam fields on an X-ray simulator with bony anatomy
provides the bulk of the guidance. The target was identified on a planar X-ray, and areas not
to be treated were blocked, originally with lead or cerrobend alloy, converting a square or a
rectangular beam offered by the machine into an irregularly shaped beam, at least in two
directions. Bony anatomy visualized on plain radiographs was the primary method of
determining field placement using orthogonal, and occasionally oblique or vertex fields. The
uncertainty in target determination with this rudimentary method mandated the incorpora‐
tion of error as a significant element in the radiation field design, generally resulting in large
volumes being irradiated [37]. The tremendous advancement in computers and telecommu‐
nication allowed more complex treatment planning systems (TPS). Technical advances such
as multileaf collimation (MLC), digitally reconstructed radiographs (DRRs), and electronic
portal imaging (EPI) greatly contributed to the integration of three-dimensional conformal
radiation therapy (3DCRT) effective delivery. The planning process for 3DCRT is significant‐
ly more complex than for conventional RT. Therefore, multiple well-coordinated steps are
taken by the different categories of radiation oncology team; radiation technologist, dosimet‐
rist, physicist, and radiation oncologist. With the advancement in CT technology, it became
possible to incorporate 3D data for both normal organ at risk and tumor into treatment
planning systems. This results not only to delineate targets accurately but also to calculate
radiation doses efficiently from multiple beams through multiple directions, and to block
out (and save) normal tissue more effectively, thus yielding a more conformal 3D radiation
plan.
3.1. Immobilization and imaging
The initial step of the planning process is to place the patient in a reproducible position that
optimizes treatment of the entire tumor volume while sparing surrounding critical struc‐
tures. Variable customizable immobilization devices may be used, including thermoplastic
facemasks, alpha cradles, and vacuum mattresses. It is important to ensure that these devices
are comfortable, reproducible, and sustainable along the whole radiotherapy treatment. Upon
the optimal position of the patient, localization (determining points of origin through a laser
device) is determined and marks are placed. With the patient in the treatment position, CT
images of the area of interest are obtained and the data are transferred to the planning system.
At this stage, the clinician will be able to define the target volumes as well as critical struc‐
tures. Other modalities such as MRI can be co-registered with the CT data for better determi‐
nation of the target volumes. Two main basic issues are essential for treatment planning: the
identification of the topography and geometry of the diseased tissue and the correct segmen‐
tation of the anatomy of normal tissues. The International Commission on Radiation Units and
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Measurements (ICRU) has defined evolving standard definitions for radiotherapy target
volumes. Their recent recommendations [39] include:
• The gross tumor volume (GTV), being gross demonstrable extend and location of the
malignant growth, irrespective of the method used for its detection.
• The clinical target volume (CTV), being a volume that contains a demonstrable GTV and/or
subclinical malignant disease that must be eliminated.
• The planning target volume (PTV) including the CTV and the surrounding geometrical
margin to ensure that the prescribed dose is actually delivered to the CTV with a clinical‐
ly acceptable probability.
• The organs-at-risk (OAR) tissues that need to be avoided to decrease the morbidity and
determine the exact dose to be delivered to each and to be adjusted according to the
knowledge of tolerance and normal tissue complication probability (NTCP). This OAR dose
determination may influence the treatment planning and/or the dose prescription. An
acceptable plan is the one taking in consideration both tumor coverage and OAR dose
distribution. Upon target volumes and critical structures definition, each beam geometry
and weighting are determined to calculate the final dose distribution. Beam angles selection
is performed using either the isodose distribution in axial images or the beam’s eye view
(BEV). BEV visualizes the relationship of tumor volumes to those of critical OAR, as if
looking from the origin of the beam. Once an initial plan has developed, the resulting dose
distributions are calculated and evaluated by the clinician. Accurate quantification of
radiation doses to the normal structures will allow the choice of the prescribed maximum
dose to the target simultaneously with minimum dose to the normal structures to pro‐
duce a better therapeutic ratio. Consequently, more accurate shielding of normal struc‐
tures is ensured using MLC. These data are represented graphically on a dose–volume
histogram (DVH), presenting information pertinent to the adequacy of tumor dose and
maintaining the normal tissue doses below safe thresholds. Conformal RT is the most
common treatment used for primary brain tumors; however, the use of IMRT is rapidly
increasing. Plans whether conformal or IMRT are evaluated by viewing isodose curves on
serial images of a CT scan, as well as by the generation of DVH for tumor volume as well
as other normal tissues or organ of interest. This allows the radiation oncologist to evalu‐
ate the dose delivered to the total volume (tumor volume and OAR). DVHs are graph
percent volume of a given tissue on the Y-axis and dose on the X-axis allowing the visual‐
ization of the percentage of a defined structure receiving a given dose. These data allow
plans to be modified as needed to either increase dose delivered to tumor or decrease dose
to a nearby critical structure.
Once a satisfactory plan is generated, digital reconstructive radiograms (DRRs) correspond‐
ing to the planned radiation fields are obtained. These DRRs typically display field shapes and
tumor volumes and the standard radiographic anatomical information. Using a complex 3D
plan, MLC allows for rapid change of field shape under computer control, dramatically
shortening the time needed to treat a patient. A verification simulation can be performed to
check the validity and accuracy of the fields. This can be performed with the use of an electronic
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portal-imaging device (EPID) or a cone beam CT (CBCT). CBCT generates an image of the
tumor and all surrounding normal structures using the same linear accelerator with which the
patient is being treated. Linear accelerators produce the images of CBCT through either the
same treating megavoltage beams (MV-CBCT) or built-in kilovoltage device (KV-CBCT).
Appropriate adjustments of the exact treatment position can then be made daily to ensure that
the tumor is receiving the prescribed dose of radiation, and normal tissues are receiving doses
within their tolerance range. Recently, there are different devices for setup accuracy using
either ultrasonography, infrared, radiofrequency for verification or setup positioning and to
deal with intra-fractional movements.
The major hypothesized benefits of IMRT are a reduction in the dose to normal structures, as
well as the potential for dose escalation. In IMRT, radiation beam is subdivided into a very
large number of optimized small beamlets each with a unique intensity of radiation, influ‐
enced by the patient’s anatomy in the path of the beamlet allowing tailored radiation dose
distributions, to both the tumor and normal tissues. Three-dimensionally concave or convex
shape configuration is one of the important characteristics of IMRT, resulting in a dramatic
reduction of high doses of radiation to normal structures near the target. Moreover, it allows
for differential doses to be delivered within the same target, giving the component at higher
risk of recurrence higher dose while the rest of the target is being treated to a conventional
dose. This technique is called simultaneous integrated boost (SIB). This is attractive in certain
situations, in that it allows a higher dose per fraction to the target, while giving a lower dose
per fraction to normal structures. Biologically effective dose (BED), which is calculated based
on the linear-quadratic (LQ) model, is commonly used on trial to relate the unconventional
dose to that for the well-known conventional fractionation.
The main disadvantage of IMRT, in some instances, is the increase in low doses to normal
tissues leading to increase in the body integral dose (i.e., higher total dose of a large volume).
Other challenges of IMRT are the rapid fall-off of dose; therefore, patient immobilization and
daily setup verification become critical. Slight motion or setup error may result in a geograph‐
ic miss; the high dose is deposited in the critical structure designated for avoidance. Therefore,
it is always stated that daily setup verification better precedes IMRT especially if proximity of
a nearby critical structure is a concern. Fortunately, the brain moves minimally, and stand‐
ard immobilization devices yield relatively high daily setup accuracy. Because IMRT dose
distributions are highly complex, it is not unusual to see unanticipated toxicities in low-dose
areas, such as alopecia or mucositis, in the exit-beam regions [7]. Increased incidence of second
malignancy was postulated as a serious late side effect. However, it remains unclear wheth‐
er second malignancies are a real or a hypothetical risk [40]. Intensity-modulated radiothera‐
py has several potential benefits in specific CNS tumors. Medulloblastoma represents a good
example that is treated after surgery with radiotherapy and cisplatin-based chemotherapy,
and radiation. Both platinum and radiotherapy significantly contribute to the occurrence of
ototoxicity. However, the use of IMRT can spare the auditory apparatus (cochlea) while still
maintaining full dose to the target. Reduction in cochlear dose from 54.2 to 36.7 Gy leads to
reduction of grade 3 or 4 hearing loss from 64 to 13% with the use of IMRT, compared with
Neurooncology - Newer Developments460
conventional RT [41]. Furthermore, decreasing the cumulative dose of cis-platinum or usage
of efficient less ototoxic drug is preferable for better hearing integrity.
3.2. Image-guided radiation therapy
Image-guided radiation therapy (IGRT) is the technique of using imaging technology at the
time of each treatment to verify accurate positioning.
There are several types of IGRT including CBCT, MV CT (helical tomotherapy), CT-on-rails,
the use of electronic portal imaging devices (EPIDs), ultrasound guidance radiofrequency, and
fiducial monitoring. Advances in IGRT have allowed selective boost of dose to some targets
while at the same time selectively sparing normal structures more aggressively.
3.3. Stereotactic radiosurgery and stereotactic fractionated radiotherapy
The term radiosurgery was selected because of its similarity to stereotactic neurosurgery.
Radiosurgery technology has become increasingly more available, and its application has
widened. Its current indications include arteriovenous malformations, benign brain tumors,
malignant brain tumors, and functional disorders. Delivery of radiosurgery is complex and
coordination of care by the neurosurgeon, radiation oncologist, and medical physicist is
essential. Appropriate coordination leads to improved quality of care, reduction in practice
variation, and improved patient satisfaction [42].
Radiosurgery entails a single treatment, whereas conventional RT used multiple treatments.
Further, in conventional fractionation regimens, normal brain tissue adjacent to the target
receives a considerable dose of radiation. Taking into consideration late toxicity, radiosur‐
gery is able to treat with considerably high-dose gradients adjacent to a nonmobile target that
makes its use in the brain ideal. The use of a very large number of beams (significantly
modulated beams) ensures that the geometry provides ideal physical dose distribution for
targets less than 4 cm in greatest dimension with maximally low dose to surrounding tissues.
Beyond this limit, it is difficult to achieve a rapid fall-off in these normal tissues. Radiosur‐
gery can be performed using various devices, including the gamma knife, particle beam
devices, or modified linear accelerators (X-knife, cyberknife). With the great technologic
advances in software and hardware, there is no clear advantage of one technology over the
other [43]. The linear accelerator-based units can serve to treat non-radiosurgery patients.
Radiosurgery and neurosurgical approaches are often complementary, with the advantage
that radiosurgery does not require a craniotomy, nor general anesthesia and patients are
usually discharged the same day.
3.4. Charged particles
Proton beam therapy gained great interest in the radiation oncology community especially the
pediatric one. This is related mainly to the dosimetric advantages of protons. Proton beam
deposits its energy rapidly in what is known as the Bragg peak, a narrow range energy
deposition where at the end of its path length the particle slows and. delivers radiation with
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a rapid fall-off. This confines the radiation to a smaller volume (clinical tumor volume) and
extremely reduces the exit dose. The beam stops at a given depth that depends on their initial
energy. Therefore, the possibility of wide low doses of radiation to normal tissues is mini‐
mal; different from IMRT. The dose fall-off beyond the Bragg peak is very rapid, reaching zero
within a few millimeters beyond the maximum [44–46]. Despite the lack of Level 1 evidence,
retrospective studies do exist to support its use in pediatric intracranial lesions. Traditional
proton therapy and intensity-modulated proton therapy (IMPT) resulted in more efficient
sparing of normal tissue compared to photon-based IMRT [47]. A model was designed to
predict neurocognitive dysfunction after RT. The reduction in lower-dose volumes and mean
dose afforded by proton therapy might reduce the incidence of late-term sequelae in chil‐
dren with medulloblastomas, craniopharyngiomas, and optic-pathway gliomas [48].
4. Chemotherapy
Chemotherapy is an essential modality in the treatment of many childhood malignancies
including brain tumors. A wide variety of chemotherapeutic agents proved to be effective for
most types of brain tumors. The role of chemotherapy varies from delaying the RT timing to
allow further development of brain functions in the young, stabilizing tumors, reducing
radiation doses, or even avoiding RT altogether. Effective agents include many alkylating
agents, vinca alkaloids, topoisomerase inhibitors, antimetabolites, and angiogenesis inhibitors.
Chemotherapy for brain tumors can be given by various routes, including orally, intrave‐
nously, intrathecally, and via an Ommaya reservoir. Furthermore, chemotherapy may be given
as an adjuvant or as concomitant with radiotherapy, improved survival for many pediatric
brain tumors including medulloblastoma, germ cell tumor, high-grade astrocytoma, and
others. In other conditions, like ependymoma, chemotherapy may be used to increase resect
ability of the tumor [49].
The blood-brain barrier is a dynamic interface separating the brain from the circulatory system.
The blood-brain barrier regulates the transport of essential molecules from the circulation to
the brain, protecting the brain from harmful chemicals. It limits the ability of many chemo‐
therapy agents to penetrate into the CNS. There are mechanisms such as blood-brain barrier
disruption, intra-arterial chemotherapy injection, intrathecal chemotherapy administration, or
intratumoral chemotherapy administration which were utilized to overcome the blood–brain
barrier.
4.1. Intrathecal chemotherapy
Intrathecal administration of chemotherapy is another method of bypassing the blood-brain
barrier to deliver chemotherapy within the CNS. Many agents have been investigated for a
variety of brain tumors. Intrathecal liposomal cytarabine, mafosfamide, and etoposide were
used in children with ependymoma, primitive neuroectodermal tumor, medulloblastoma, and
atypical teratoid rhabdoid tumor [50].
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4.2. Intra-ommaya therapy
Ommaya reservoirs were placed directly into the lateral ventricle to prevent repeated lumbar
punctures for intrathecal chemotherapy. These provide easy access to the intrathecal space.
Ommaya reservoirs have also been placed into the cysts of craniopharyngiomas in order to
deliver chemotherapy agents intratumorally. The two agents that have previously been
successfully utilized using this method of drug delivery are bleomycin and alpha interferon
[51, 52].
5. Supportive care
Supportive care describes the multidisciplinary care required to fulfill the needs of the patient
and family in order to meet the physical, informational, psychosocial, emotional, practical, and
spiritual needs during all phases of their cancer care [53]. The treatment of pediatric brain and
spinal cord tumors is complex and every family is different, with variable needs throughout
treatment. This requires a collaborative and multidisciplinary health-care team to effectively
assess and address the required supportive care early during the stage of diagnosis or initial
therapy [53, 54].
The supportive care needs of pediatric patients and their families include the physical
(physiotherapy, occupational therapy, speech pathology, dietician, medical, pharmacy),
education/informational (often met by nursing and medical team members), as well as
psychosocial (social work, psychology, child life, psychiatry). It is important to reassure the
family that the intense emotional reactions (including fear, powerlessness, denial, guilt,
sadness, anger, confusion, anxiety, and depression) are normal responses to the child’s illness
and that the team is there to support and not judge them. Complete family assessment
including psychosocial and practical resources, employment, socioeconomic status, as well as
an assessment of marital-parental and sibling relationships should be studied and managed
[54]. Misunderstanding may influence care [54].
5.1. Informational needs
Good communication by the health-care team, repetition of information, opportunities to ask
questions, and written materials are important for assisting families. Gaining information
about their child’s condition allows parents to feel some control over the situation and regain
some peace of mind. Psychosocial providers can assist families to manage feelings of infor‐
mation overload and problem solving according to the demands.
Parents may require guidance from the team regarding how and when to talk to their children,
to do it so honestly and at an age-appropriate level, yet in a way that decreases anxiety and
increases trust in the treatment process and team.
Normalizing activities as much as possible can be of great help in restoring a sense of safety
and normalcy for children. Child life specialists can help to normalize daily activities. Once
the child is discharged from the hospital, encourage parents to allow the child to live life as
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normal as possible. Social and medical staff have to help the parents to overcome their own
fears, and to allow patients to return to pre-illness activities within the restrictions of the illness
with no overindulging or overprotecting [54].
5.2. Nutritional support
It is well established that children and adolescents with cancer experience malnutrition due to
their underlying malignancy and treatment-related factors. Diminished nutritional status
contributes in poor wound healing, increased infection risk, and decreased tolerance to
chemotherapy. It is established that poor nutrition affects the QoL, response to treatment, and
overall cost of care. This may be attributed to their limited energy stores and increased
nutritional requirements to attain their appropriate growth and neurodevelopment [57–58].
Nutritional strategies should be integrated as a fundamental feature of supportive care for all
pediatric neuro-oncology patients. The goals of nutritional supportive care include the
maintenance of body stores, minimization of weight loss, promotion of appropriate growth,
and providing excellent QoL [58].
5.3. Endocrinopathy at diagnosis and during treatment of brain tumor
Tumors of suprasellar and pineal region show various endocrine abnormalities even before
the start of any treatment. Endocrinal symptoms in midline tumors include diabetes insipi‐
dus; changes in weight, height, and growth velocity; precocious puberty; or delayed sexual
development. These symptoms less often lead to diagnosis, despite being present long before
diagnosis [59]. Hypothalamic and pituitary endocrinopathies occur commonly in children
following ≥24 Gy whole brain or localized cranial RT that included these structures in the
radiation field. Hypothalamic-pituitary axis dysfunction gives rise to endocrinal abnormali‐
ties. This could be permanent or transient and the pituitary gland may regain its ability to
secrete hormones after treatment. Therapeutic modalities, including surgery and radiothera‐
py, can damage pituitary cells leading to worsening of preexisting hypopituitarism [60].
Careful history and clinical examination, as well as timely reevaluation of children with
abnormal body mass index (BMI) or BMI progression, as the presence of other neurological,
ophthalmologic, and endocrine signs and symptoms may be indicative of the presence of an
underlying hypothalamic-pituitary lesion [59, 60].
6. Long-term sequelae
The high cure rate achieved in pediatric CNS tumors is greatly attributable to refined
neurosurgical procedures, the advancement in RT as well as chemotherapy and the multidis‐
ciplinary team decisions for treatment. However, with prolonged survival and on reaching
adulthood, the incidence of late effects becomes more apparent. A majority of long-term
survivors have at least one chronic medical sequelae [61]. These complications include
endocrinopathy, osteoporosis, cerebrovascular disease, neurological and neurosensory
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dysfunction, secondary neoplasms, as well as psychological consequence and neurocogni‐
tive impacts.
6.1. Growth
Radiation-induced growth deficiency is due to damage to either hypothalamus or pituitary
gland or local radiation to the spine. Cranial irradiation has an immediate suppressive effect
on the hypothalamic-pituitary axis. According to the total cranial dose received, it reduces
growth hormone (GH) level and alters the normal pubertal rise in GH secretions. The size and
the number of radiation fractions influence growth hormone levels. Early diagnosis of mild
hypothyroidism and/or GH deficiency permits early intervention to improve growth veloci‐
ty and QoL [62]. Craniospinal irradiation and/or disruption of the pituitary-hypothalamic axis
can lead to more global changes in physical appearance such as short stature or obesity [62, 63].
Spinal radiation will affect vertebral body growth, especially in the younger ages. Chemo‐
therapy may impair gonadal function, usually more in males than in females. Cyclophospha‐
mide-induced testicular damage is dose dependent. In general, prepubertal patients tend to
be more resistant to gonadal adverse effects of RT and chemotherapy than postpubertal
patients [62].
6.2. Osteoporosis
Brain radiation, corticosteroids, poor nutrition, restricted weight-bearing exercise, and the
developed endocrinopathies interact and all affect bone mineral density (BMD) during a
crucial period for bone growth and skeletal growth. Depending on the magnitude of the BMD
deficit and the potential for recovery, the pediatric neuro-oncology survivors are at in‐
creased risk for osteoporosis that may lead to osteoporotic fractures later in life.
These survivors should be assessed for low BMD and referred for potential bone health
assessment and treatment as well as maximizing nutrition, exercise, and calcium and vita‐
min D intake [64].
6.3. Sleep disorder
Neuro-oncology patients may suffer from sleep disorders including disturbed sleep-wake
rhythm, increased sleep duration, disturbed sleep timing, and daytime sleepiness that
significantly affect their daily performance and their QoL. Disturbed pattern of sleep is more
often experienced in children suffering from hypothalamic, pituitary, or brain stem lesions as
well as in those treated with craniospinal radiotherapy. Excessive somnolence and psychoso‐
cial functioning with fatigue are common complaints of such patients. Routine evaluation of
sleep habits during may help better understanding the mechanisms underlining these
disorders and present possible interventions (e.g., melatonin, cognitive therapy, bright light
therapy, medications, and/or physical activities) [65].




An increased risk of vascular malformations was noticed with radiotherapy. Radiation can
weaken the vessel wall and result in cerebral cavernous malformation, telangiectasias of
capillaries, and aneurysms. Radiation is believed to stimulate angiogenesis factors leading to
these vascular malformations. Cerebral cavernous malformations were experienced six times
higher in those treated with radiotherapy than in the control population. Most of these lesions
are asymptomatic, but a subset may be presented with seizures, headaches, and hemorrhag‐
es that may require surgical intervention.
Telangiectasias are commonly found in brain tissue obtained from patients treated with
radiotherapy, with thin-walled, dilated tortuous vascular channels, associated with perivas‐
cular leukocyte infiltration. These abnormalities may become symptomatic after bleeding but
are usually considered as benign finding [66].
Small vessel vasculopathy with mineralizing microangiopathy of the basal ganglia and
subcortical white matter has also been reported months to years after completion of radia‐
tion of the brain [67]. Most patients are asymptomatic, but some investigators have correlat‐
ed their presence with behavioral disorders, neurological deterioration, and dementia.
Moyamoya vasculopathy was reported in pituitary and chiasmatic tumor patients treated with
and without radiation. This vasculopathy is a progressive stenosis of the supraclinoid internal
carotid arteries leading to the development of collateral blood vessel formation. Radiation to
the circle of Willis and neurofibromatosis type I (NF1) have been identified as risk factors [28].
6.5. Seizures
Childhood Cancer Survivor Study (CCSS) reported the prevalence of epilepsy in long-term
survivors of childhood brain tumors as 25%. Many of them had their first seizure more than
5 years after diagnosis of their cancer [68]. Seizures were more frequent in patients treated with
RT >30 Gy to any cortical area and more frequent in children treated at young age or who
underwent repeated brain tumor excisions. Methotrexate has also been related to late seizure
onset, especially with the resulted necrotizing leukoencephalopathy.
6.6. Ototoxicity
High doses of platinum have been reported to cause irreversible early- or delayed-onset
hearing loss. Platinum targets the outer hair cells in the organ of Corti and the cochleal wall
epithelium. These late complications create hearing affection and hence affect speech devel‐
opment, learning, communication, school performance, social interaction, and overall QoL.
Platinum ototoxicity is characterized by a dose-dependent high-frequency sensorineural
hearing loss with tinnitus. The magnitude of ototoxicity was influenced by the young age at
the start of treatment, the high cumulative doses of platinum compounds (>400 mg/m2 for
cisplatin and carboplatin), and the use of concomitant ototoxic treatments including CNS RT
[69]. Genetic polymorphisms in enzymes responsible for platinum metabolism (e.g., gluta‐
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thione S-transferase, thiopurine methyltransferase, catechol O-methyltransferase) may
contribute to the severity of hearing loss [70, 71].
RT to the cochlea or cranial nerve VIII can also cause sensorineural hearing loss. Cranial RT
used alone results in ototoxicity when cochlear dosage exceeds 32 Gy. Young age, presence of
a brain tumor, and/or hydrocephalus can increase susceptibility to hearing loss. When used
concomitantly with platinum, RT can have a synergistic effect and it substantially exacer‐
bates the hearing loss associated with chemotherapy, especially in the high-frequency speech
range. RT to temporal lobe (>30 Gy) and to posterior fossa (≥50 Gy) was reported to be
associated with an increased risk of tinnitus, and hearing loss.
Early detection of ototoxicity in children is of extreme importance in the prevention of severe
hearing impairment that may affect speech recognition. Various strategies have been consid‐
ered to minimize platinum ototoxicity. Radiation reduction dose to the cochlea has been
investigated, including the use of 3D conformal RT, IMRT, and proton therapy [72]. Once
treatment is completed, long-term audiometric monitoring should continue.
6.7. Visual affection
CCSS reported in adult survivors of childhood brain tumors, blindness in one or both eyes
in 13%, cataracts in 3%, and double vision in 17% [68]. Although cataracts are known compli‐
cation of RT, prolonged use of corticosteroid such as dexamethasone can also contribute to the
development of posterior subcapsular cataracts. Ophthalmologic complications were report‐
ed in optic pathway glioma and craniopharyngioma in 20–70% of patients. Poor visual
outcome has been frequently reported in the posterior chiasmatic area. Long-standing
obstructive hydrocephalus can lead to severe optic atrophy and blindness.
6.8. Secondary neoplasms
The increase in survival in childhood tumors was accompanied with the emergence of
secondary neoplasms as a long-term complication of treatment reaching up to 3–4% at 20 years
post treatment [73]. Leukemia and primary CNS tumors have a tendency to develop into a
subsequent CNS tumor. Armstrong et al. [74] reported 20 (1.1%) second CNS tumors out of
1877 survivors of CNS malignancies. They also observed 171 (9.1%) neoplasms classified as
“benign” tumors including 59 meningiomas and 112 nonmelanoma skin cancers in these long
survivors. The overall cumulative incidence of a subsequent neoplasm at 25 years was
estimated to be 10.7%. Generally, the most common malignancies are malignant astrocyto‐
mas, followed by sarcomas and occasionally supratentorial primitive neuroectodermal
tumors (sPNET). The cumulative incidence of secondary CNS such as glioblastomas pla‐
teaued at 15 years, whereas the cumulative incidence of meningiomas continues to increase
beyond 35 years post treatment [75]. Although these secondary tumors have similar histolog‐
ical appearance to the primary tumors, they typically behave more aggressively and are
resistant to treatment [76]. Moreover, the meningiomas have also been found to be more often
atypical and prone to relapse. The development of secondary CNS tumors is most likely
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multifactorial, but RT certainly contributes to this process. The vast majority of secondary
malignant neoplasm (SMN) appears within the radiation field. The cumulative incidence of
SMNs at 25 years was 7.1% for children who received more than 50 Gy to the cranium
compared to 1% for children who did not receive cranial irradiation. A linear dose response
could be illustrated with an increased relative risk of 0.33% for gliomas and 1.06% for
meningiomas per Gy. The chemotherapy contribution to the development of secondary CNS
malignancy is more difficult to assess partly due to the use of combination chemotherapy
regimens. Alkylating drugs, especially cyclophosphamide and epipodophyllotoxins, such as
etoposide, have been reported to increase the cumulative incidence of second malignancies
[77]. The presence of accompanying somatic mutations may predispose for the development
of second malignancy. Patients with p53 (Li-Fraumeni syndrome) are more likely to develop
SMN including sarcoma, primary brain tumor, and acute lymphoblastic leukemia (ALL).
Therapy may be tailored in order to avoid or reduce the combination of RT and certain
chemotherapy agents. Alkylating drugs, especially cyclophosphamide and epipodophyllo‐
toxins, such as etoposide, have been reported to increase the cumulative incidence of second
malignancies up to 4% [77]. Other somatic mutations such as the ataxia telangiectasia mutated
gene (ATM) known to be involved in DNA repair may possibly play a role. Finally, metabo‐
lism and detoxification might also be involved in the development of second malignancy
especially in those with acute nonlymphocytic leukemia (ANLL) and acute myeloid leuke‐
mia (AML).
7. Palliative care
Palliative care for children has evolved, over the last two decades, as separate specialized
entity. Its delivery encompasses the total care of children with life-limiting diseases, regard‐
less of outcome. It is worth noting that palliative care is applicable from the time of diagno‐
sis, through active and curative treatment, and afterwards. Timing is further complicated by
the perceived sharp division between curative therapy and palliative care among pediatric
oncologists and parents who view palliative care as giving up hope and representing failure.
Palliative care service includes improved communication and continuity of care across
different disease and management stages. This care deals with assessment of physical,
psychosocial, emotional, and spiritual needs, provision of comprehensive specialized pain and
symptom management, and support with complex and ethical decision making. It is also
concerned with enhanced awareness of diverse cultural beliefs about dying and death,
specialized care of the dying patient, and provision of bereavement care. Education and staff
support to improve delivery of care and respond to moral distress are additional important
role [78, 79]. Palliative care services must better be organizationally situated within a pedia‐
tric oncology program. Without early integration of palliative care, the focus of care then
centers on life-prolonging measures, which may result in painful and invasive procedures,
additional unnecessary suffering, and futile resuscitation. Care may be missed if not ad‐
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dressed early in the trajectory of a cancer illness when death is expected. However, the pediatric
brain tumor palliative care introduction time remains unclear and controversial, and has little
evidence for practice guidelines [78].
8. Conclusion
Although the gap between the neuro-oncology services in HICs and LMICs is still huge, yet
the continuous efforts performed by the LMICs assisted by different international organiza‐
tion, medical and scientific societies, and other international medical bodies can decrease and
overcome this gap. Pediatric neuro-oncology service is a delicate art and science that is
presented by a multidisciplinary team aimed at taking care of pediatric CNS tumors from the
day of suspicion of the disease till long way across the adulthood life. The welfare of these
patients is the concern of the multidisciplinary team along the journey of diagnosis, treat‐
ment, and prolonged extended follow-up. The team is concerned also with dealing with
disease and treatment complications together with palliation of the symptoms faced by the
patients. Much success was achieved; however, much effort is needed for more improve‐
ment of the quality of their life. Very long-term effects 30–40 years after treatment still need to
be thoroughly investigated. Cerebrovascular diseases such as stroke, cognitive dysfunction
leading to early dementia, secondary neoplasms, and peripheral neuropathy are likely to form
real problem in the coming years.
The balance between survival and long-term side effects will certainly be a challenge for several
decades. Tailored therapy to reduce and limit the need for radiation and chemotherapy will
hopefully lead to improved outcomes with fewer adverse effects and morbidity.
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